36147
2-甲-4-氯丙酸
PESTANAL®, analytical standard
别名:
2-(4-氯-2-甲基苯氧基)丙酸
等级
analytical standard
质量水平
产品线
PESTANAL®
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
agriculture
environmental
包装形式
neat
SMILES字符串
CC(Oc1ccc(Cl)cc1C)C(O)=O
InChI
1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)
InChI key
WNTGYJSOUMFZEP-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
应用
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
法律信息
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
农药列管产品
此项目有
Pablo J Maid et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 24(4), 177-182 (2017-12-13)
Biologic agents may induce immune responses that could impact drug action. The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit
Jeffrey Vietri et al.
Human vaccines & immunotherapeutics, 16(1), 161-168 (2019-07-26)
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Data
Julien Taieb et al.
Drugs, 79(13), 1375-1394 (2019-07-28)
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to optimise efficacy, while minimising toxicity. As
Yutaka Osuga et al.
Obstetrics and gynecology, 133(3), 423-433 (2019-02-12)
To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment
Régis Peffault de Latour et al.
British journal of haematology, 191(3), 476-485 (2020-05-26)
Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持